Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

J&J: Strong sales growth in McNeil's Viactiv chewable calcium supplements was "substantially offset" by declines in adult analgesics, Imodium franchise during Q3, J&J reports in 1quarterly release and analysts call Oct. 15. Tylenol, Motrin marketer says Q3 adult analgesic sales compared unfavorably to year-ago period, "when retail inventories were built in anticipation of the fourth quarter flu season. Retailers are being more conservative this year and not stocking in similar fashion," according to J&J VP-Investor Relations Helen Short. Imodium also suffered in comparison to year-ago quarter, when Imodium Advanced caplets launched. McNeil worldwide sales rose a slight 1% to $448 mil. for the quarter, with U.S. sales gaining 3% to $387 mil. and international sales dropping 12% to $61 mil...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS094685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By